上海勁馬實驗設備有限公司是一家專業(yè)從事免疫學、細胞學、化學試劑代理商，現在本公司可代理美國ATCC細胞、美國Sciencell細胞，美國CHI細胞，同事我公司也有種類齊全的傳代細胞，所有細胞都附有傳代情況及培養(yǎng)說明。我公司現在與美國公司合作，接受客戶原代細胞定做，只限于人和小鼠正常組織細胞，細胞zui小量100萬個，歡迎有需要的客戶前來咨詢。 ： 何

 

人乳腺癌細胞株 4T1

Price: $279.00 

Designations: 4T1 

Depositors:   BA Pulaski 

Biosafety Level: 1 

Shipped: frozen 

Medium & Serum: See Propagation 

Growth Properties: adherent

Organism: Mus musculus （mouse） 

Morphology: epithelial

 

 

Source: Organ: mammary gland

Strain: BALB/cfC3H

Disease: tumor

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimay responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. 

 

Tumorigenic: Yes 

Comments: 4T1 is a 6-thioguanine resistant cell line selected from the 410.4 tumor without mutagen treatment. [49690]

When injected into BALB/c mice, 4T1 spontaneously produces highly metastatic tumors that can metastasize to the lung, liver, lymph nodes and brain while the primary tumor is growing in situ. [49688] [49690]

The primary tumor does not have to be removed to induce metastatic growth.

The tumor growth and metastatic spread of 4T1 cells in BALB/c mice very closely mimic human breast cancer. This tumor is an animal model for stage IV human breast cancer. [49688] [49689]

4T1-induced tumors can be used as a post-operative model as well as a non-surgical model because the 4T1-induced tumor metastasizes spontaneously in both models with similar kinetics. [49687] [49688] [49689]

Because 4T1 is resistant to 6-thioquanine, micro-metastatic cells （as few as 1） can be detected in many distant site organs with better accuracy that most tumor models. There is no need to count nodules or weight target organs. [49687] [49688] [49689]

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Atmosphere: air, 95%; carbon dioxide （CO2）, 5%

Subculturing: Protocol: NOTE: the cells should not be allowed to become confluent, subculture at 80% of confluence. Remove medium, and rinse with 0.25% trypsin-0.53mM EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature （or at 37.0°C） until the cells detach. Add fresh culture medium, aspirate and dispense into new culture flasks.

Subc*tion Ratio: A subc*tion ratio of 1:6 to 1:8 is recommended

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor temperature

Related Products: Recommended medium （without the additional supplements or serum described under ATCC Medium）:ATCC 30-2001

recommended serum:ATCC 30-2020

References: 49687: Pulaski BA, et al. Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. Cancer Immunol. Immunother. 49: 34-45, 2000. PubMed: 10782864

49688: Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res. 58: 1486-1493, 1998. PubMed: 9537252

49689: Pulaski BA, et al. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res. 60: 2710-2715, 2000. PubMed: 10825145

49690: Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52: 1399-1405, 1992. PubMed: 1540948